Quest Magazine

Shape of Genetic Material Matters in C9ORF72-Related ALS

MDA Thrilled FDA Will Consider Accelerated Approval for New Muscle Disease Drug Aimed at DMD

Dutch Bros. Coffee Annual “Drink One for Dane” Day to Donate Proceeds to Muscular Dystrophy Association

MTM: Down With Dynamin 2

A French research team has found that reducing levels of a protein called dynamin 2 has potential as a strategy to treat myotubular myopathy (MTM), a form of centronuclear myopathy (CNM), and that it could have implications for other nerve and muscle disorders as well.

MDA to Fund 38 New Research Grants

Siblings of Children with Neuromuscular Diseases Need Attention, Too

"Anything we can say about being a parent of a person with special needs we can pretty much say for being a sibling of a person with special needs," said Don Meyer, director of the Sibling Support Project based in Seattle.

Meyer talked about siblings of people with disabilities at the 2014 MDA Clinical Conference in Chicago during an afternoon session titled "Specialized Care," held March 18.

Leading the Way: MDA’s critical support for people with ALS

For many, amyotrophic lateral sclerosis is a fast disease. Once diagnosed, the average life expectancy for a person with ALS can be as few as three to five years. When Ben Thomas received his ALS diagnosis at the age of 29 — just three months after the birth of his only daughter, Emmerson — his world was turned upside down.

MDA is the world leader in funding ALS research and services.

Pain in Neuromuscular Diseases: Who Knew?

Sailormen Inc. Popeyes “Appetite for A Cure” Raises Record $539,863 for MDA

New Forms of Genetic Testing Improve Diagnosis, Raise Questions

“Knowing, if not all, is almost all,” said Matthew Harms, a neurologist and neurophysiologist from Washington University in St. Louis, in his presentation on genetic testing for neuromuscular disorders at the 2014 MDA Clinical Conference, held in Chicago March 16-19.

Pages